Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054899 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Epimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00054899 is a Phase 1 study that has completed, run by Epimmune. The registered enrollment target is 18 participants.
The verdict
NCT00054899, a Phase 1 study, has completed, sponsored by Epimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Non-Small Cell Lung Cancer.
Interventions
- BIOLOGICAL EP2101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054899
The ClinicalTrials.gov registry entry for NCT00054899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epimmune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EP2101 is the first listed.
NCT00054899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054899 about?
NCT00054899 is a clinical study titled "An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer". EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating ...
What is the current status of trial NCT00054899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-01.
What interventions are being tested in trial NCT00054899?
The interventions under investigation include: EP2101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054899?
This trial is sponsored by Epimmune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.